-
2
-
-
84904568743
-
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel
-
Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410-25.
-
(2014)
JAMA
, vol.312
, pp. 410-425
-
-
Gunthard, H.F.1
Aberg, J.A.2
Eron, J.J.3
-
5
-
-
84255173321
-
Antiretroviral drug interactions: Overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management
-
Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 2011; 3:745-81.
-
(2011)
Pharmaceutics
, vol.3
, pp. 745-781
-
-
Rathbun, R.C.1
Liedtke, M.D.2
-
6
-
-
84904647749
-
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
-
e1
-
Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359-65.e1.
-
(2014)
Gastroenterology
, vol.147
, pp. 359-365
-
-
Andreone, P.1
Colombo, M.G.2
Enejosa, J.V.3
-
7
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
-
(2014)
N Engl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
-
8
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
9
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
-
(2014)
N Engl J Med
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
-
10
-
-
84925428093
-
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial
-
Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-31.
-
(2015)
JAMA
, vol.313
, pp. 1223-1231
-
-
Sulkowski, M.S.1
Eron, J.J.2
Wyles, D.3
-
11
-
-
84928334037
-
Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors
-
5-9 September; Washington, DC
-
Khatri A, Wang H, Wang T, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
-
(2014)
Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Khatri, A.1
Wang, H.2
Wang, T.3
-
12
-
-
84964830595
-
-
Rockville, MD: Food and Drug Administration, Accessed 27 January 2016
-
Center for Drug Evaluation and Research (CDER). Application number: 206619Orig1s000 summary review for regulatory action. Rockville, MD: Food and Drug Administration, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206619Orig1s000SumR.pdf. Accessed 27 January 2016.
-
(2014)
Application Number: 206619Orig1s000 Summary Review for Regulatory Action
-
-
-
13
-
-
84928569640
-
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
-
Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20-9.
-
(2015)
J Hepatol
, vol.63
, pp. 20-29
-
-
Menon, R.M.1
Badri, P.S.2
Wang, T.3
-
14
-
-
75149116931
-
Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone
-
Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009; 50:91A.
-
(2009)
Hepatology
, vol.50
, pp. 91
-
-
Rodriguez-Torres, M.1
Lawitz, E.2
Cohen, D.3
-
15
-
-
84931582726
-
12-week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon - + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-naïve subjects
-
17-20 February; Bangkok, Thailand
-
Gaultier IA, Cohen DE, Dumas EO, Larsen LM, Podsadecki TJ, Bernstein B. 12-Week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon - + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-naïve subjects. Presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver; 17-20 February 2011; Bangkok, Thailand.
-
(2011)
Presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver
-
-
Gaultier, I.A.1
Cohen, D.E.2
Dumas, E.O.3
Larsen, L.M.4
Podsadecki, T.J.5
Bernstein, B.6
-
16
-
-
84866784148
-
ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis
-
Sullivan GJ, Rodrigues-Torres M, Lawitz E, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatology 2012; 56: S480.
-
(2012)
J Hepatology
, vol.56
, pp. S480
-
-
Sullivan, G.J.1
Rodrigues-Torres, M.2
Lawitz, E.3
-
17
-
-
84871765489
-
Exploratory study of oral combination antiviral therapy for hepatitis C
-
Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.
-
(2013)
N Engl J Med
, vol.368
, pp. 45-53
-
-
Poordad, F.1
Lawitz, E.2
Kowdley, K.V.3
-
18
-
-
84964916095
-
Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection
-
Epstein M, Felizarta F, Marbury T, et al. Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection. J Hepatol 2013; 58:S484.
-
(2013)
J Hepatol
, vol.58
, pp. S484
-
-
Epstein, M.1
Felizarta, F.2
Marbury, T.3
-
19
-
-
84892591928
-
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1
-
Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.
-
(2014)
N Engl J Med
, vol.370
, pp. 222-232
-
-
Kowdley, K.V.1
Lawitz, E.2
Poordad, F.3
-
20
-
-
84964901252
-
Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study
-
24-27 October 2014; Madrid, Spain
-
Sekar V, De Paepe E, Van Baelen B, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study. Presented at: 11th Annual European AIDS Conference; 24-27 October 2014, 2007; Madrid, Spain.
-
(2007)
Presented at: 11th Annual European AIDS Conference
-
-
Sekar, V.1
De Paepe, E.2
Van Baelen, B.3
-
22
-
-
84878550510
-
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twicedaily darunavir/ritonavir (DRV/r) in the ODIN trial [abstract]
-
Sekar V, De La Rosa G, Van de Casteele T, Spinosa-Guzman S, Vis P, Hoetelmans RMW. Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twicedaily darunavir/ritonavir (DRV/r) in the ODIN trial [abstract]. J Int AIDS Soc 2010; 13:P185.
-
(2010)
J Int AIDS Soc
, vol.13
, pp. 185
-
-
Sekar, V.1
De La-Rosa, G.2
Van De-Casteele, T.3
Spinosa-Guzman, S.4
Vis, P.5
Hoetelmans, R.M.W.6
-
24
-
-
84866080008
-
-
Rockville, MD: Food and Drug Administration
-
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Rockville, MD: Food and Drug Administration, 2012.
-
(2012)
Drug Interaction Studies-study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations
-
-
-
25
-
-
84957885452
-
Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen)
-
Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother 2015; 60:105-14.
-
(2015)
Antimicrob Agents Chemother
, vol.60
, pp. 105-114
-
-
Badri, P.S.1
Dutta, S.2
Wang, H.3
-
26
-
-
84964864052
-
Dose- and formulation dependent nonlinear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: Combined analyses from 12 phase 1 studies
-
Polepally A, Mensing S, Khatri A, et al. Dose- and formulation dependent nonlinear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: combined analyses from 12 phase 1 studies. J Pharmacokinet Pharmacodyn 2014; 41(suppl):S7-101.
-
(2014)
J Pharmacokinet Pharmacodyn
, vol.41
, pp. S7-S101
-
-
Polepally, A.1
Mensing, S.2
Khatri, A.3
-
27
-
-
84952984602
-
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: Combined analysis from 9 phase 1b/2 studies
-
Mensing S, Polepally A, Koenig D, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b/2 studies. AAPS J 2016; 18:270-80.
-
(2016)
AAPS J
, vol.18
, pp. 270-280
-
-
Mensing, S.1
Polepally, A.2
Koenig, D.3
-
28
-
-
70249084706
-
-
Rockville, MD: Food and Drug Administration
-
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Rockville, MD: Food and Drug Administration, 2009.
-
(2009)
Guidance for Industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation
-
-
-
30
-
-
84964857062
-
TURQUOISE-I study: Use of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with HCV/HIV-1 coinfection on stable darunavir-containing antiretroviral therapy
-
21-24 October; Barcelona, Spain
-
Ruane P, Adeyemi O, Trinh R, et al. TURQUOISE-I study: use of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with HCV/HIV-1 coinfection on stable darunavir-containing antiretroviral therapy. Presented at: 15th European AIDS Conference; 21-24 October 2015; Barcelona, Spain.
-
(2015)
Presented at: 15th European AIDS Conference
-
-
Ruane, P.1
Adeyemi, O.2
Trinh, R.3
|